Accueil   Diary - News   All news PAGE 2018 MEETING: AN IN SILICO MODEL OF HEPATITIS B VIRUS PREDICTS PATIENTS RESPONSE TO ENYO PHARMA’S DRUG CANDIDATE EYP001

PAGE 2018 MEETING: AN IN SILICO MODEL OF HEPATITIS B VIRUS PREDICTS PATIENTS RESPONSE TO ENYO PHARMA’S DRUG CANDIDATE EYP001

 

  • NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.

 

  •  Applying NOVADISCOVERY’s WISE® technology platform, the in silico model successfully reproduces the pharmacokinetics & pharmacodynamics of EYP001.

 

  • The study further anticipates the best dose for optimum antiviral response.

 

  • These first results will be presented at the PAGE 2018 in Montreux, Switzerland.

 


Lyon, May 16th, 2018 - NOVADISCOVERY, a pioneer in in silico medicine, today announces that its in silico model and first analysis of the effect of EYP001 treatment on Hepatitis B virus (HBV) infected patients will be presented at the Population Approach Group in Europe (PAGE) Meeting, May 29th – June 1st, 2018, Montreux, Switzerland. EYP001 is a synthetic non-bile acid Farnesoid X-receptor (FXR) agonist currently under clinical development by ENYO Pharma for chronic HBV infection. Following on a collaboration agreement signed with ENYO Pharma, NOVADISCOVERY has built a mathematical disease model to simulate the effect of the compound on HBV-infected virtual patients.

 


NOVADISCOVERY has applied its proprietary WISE® technology platform (Whitebox In Silico Engine), an open ecosystem that combines the company’s expertise in modeling and simulation. The two-step process has involved building a model using the literature-based, community-driven knowledge management platform GitHealth (https://githealth.io) by integrating bile acids physiology, cholesterol metabolism, HBV replication and EYP001 mode of action (MoA), the latter based on non-clinical data. The SimWork® simulation platform was then used to implement and calibrate the model, before testing by a team blinded to clinical EYP001 data on a large cohort (10,000 HBV infected virtual patients).

 

 

Read the press release